Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorLamb, Caroline Ana-
dc.creatorHelguero, Luisa A.-
dc.creatorFabris, Victoria Teresa-
dc.creatorColombo, Lucas Luis-
dc.creatorMolinolo, Alfredo-
dc.creatorLanari, Claudia Lee Malvina-
dc.date2018-02-11T22:25:50Z-
dc.date2018-02-11T22:25:50Z-
dc.date2003-05-
dc.date2017-12-28T17:49:24Z-
dc.date.accessioned2019-04-29T15:49:00Z-
dc.date.available2019-04-29T15:49:00Z-
dc.date.issued2003-05-
dc.identifierLamb, Caroline Ana; Helguero, Luisa A.; Fabris, Victoria Teresa; Colombo, Lucas Luis; Molinolo, Alfredo; et al.; Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma; Kluwer Academic/plenum Publ; Breast Cancer Research and Treatment; 79; 1; 5-2003; 25-35-
dc.identifier0167-6806-
dc.identifierhttp://hdl.handle.net/11336/36407-
dc.identifier1573-7217-
dc.identifierCONICET Digital-
dc.identifierCONICET-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/302811-
dc.descriptionThe purpose of this study was to evaluate the effect of the selective estrogen receptor modulators raloxifene and tamoxifen and of the pure antiestrogen fulvestrant on tumor growth and progesterone receptor (PR) expression in an experimental model of breast cancer. The effects of these compounds on cell proliferation were studied in primary cultures of a progestin-dependent mammary carcinoma tumor line, in the presence of medroxyprogesterone acetate (MPA) or 17-β-estradiol (E2). In in vivo studies the tumor was inoculated subcutaneously in BALB/c female mice treated with 20 mg MPA depot. Raloxifene (12.5 mg/kg) or tamoxifen (5 mg/kg) were administered in daily doses or E2 silastic pellets (5 mg) were implanted. When the tumors reached about 25–50 mm2 MPA was removed in half of the animals. E2 induced complete tumor regressions, tamoxifen inhibited tumor growth in vivo while raloxifene disclosed proliferative effects in animals in which MPA had been removed. In vitro, E2 inhibited cell proliferation at concentrations higher than 10−14 M. Raloxifene and fulvestrant, but not tamoxifen, partially reverted E2-induced inhibition. Fulvestrant and tamoxifen inhibited MPA-induced cell proliferation while raloxifene had a stimulatory effect. Tamoxifen and E2 increased, raloxifene induced no effect, and fulvestrant significantly decreased PR expression. In this study we provide evidence for differential effects of tamoxifen and raloxifene on experimental mammary tumors. Since raloxifene is under evaluation for use in breast cancer prevention, these results may have important clinical implications.-
dc.descriptionFil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.descriptionFil: Helguero, Luisa A.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.descriptionFil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.descriptionFil: Colombo, Lucas Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.descriptionFil: Molinolo, Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.descriptionFil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherKluwer Academic/plenum Publ-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1023/A:1023324827225-
dc.relationinfo:eu-repo/semantics/altIdentifier/pmid/12779079-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.subjectRALOXIFENE-
dc.subjectTAMOXIFENE-
dc.subjectFULVESTRANT-
dc.subjectMAMMARY CARCINOMAS-
dc.subjectInmunología-
dc.subjectMedicina Básica-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.subjectPatología-
dc.subjectMedicina Básica-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.subjectMedicina Química-
dc.subjectMedicina Básica-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleDifferential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.